{"id":2767,"date":"2026-02-27T22:13:48","date_gmt":"2026-02-28T03:13:48","guid":{"rendered":"https:\/\/lifetein.com\/blog\/docs\/improved-identification-of-neoantigen-reactive-t-cells-targeting-both-unique-and-common-oncogenes-for-personalized-cancer-immunotherapy\/"},"modified":"2026-03-02T10:56:16","modified_gmt":"2026-03-02T15:56:16","password":"","slug":"improved-identification-of-neoantigen-reactive-t-cells-targeting-both-unique-and-common-oncogenes-for-personalized-cancer-immunotherapy","status":"publish","type":"docs","link":"https:\/\/www.lifetein.com\/blog\/docs\/improved-identification-of-neoantigen-reactive-t-cells-targeting-both-unique-and-common-oncogenes-for-personalized-cancer-immunotherapy\/","title":{"rendered":"Improved identification of neoantigen-reactive T cells targeting both unique and common oncogenes for personalized cancer immunotherapy"},"content":{"rendered":"

Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) that target neoantigens can cause tumor regression in certain patients with metastatic epithelial cancer. However, identifying and utilizing neoantigen-reactive T cells for treatment remains challenging, and it is unclear if current detection methods miss clinically significant neoantigen reactivities. To address this, scientists explored whether enriching for T cells expressing PD-1 and\/or activation markers, followed by microwell culture to prevent overgrowth of nonreactive T cells, could improve the detection of neoantigen-reactive TILs.<\/p>\n

This linear peptide is suggested: MTEYKLVVVGAVGVGKSALTIQLI<\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) that target neoantigens can cause tumor regression in certain patients with metastatic epithelial cancer. However, identifying and utilizing neoantigen-reactive T cells for treatment remains challenging, and it is unclear if current detection … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"doc_category":[331],"doc_tag":[],"class_list":["post-2767","docs","type-docs","status-publish","hentry","doc_category-technical-protocols"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\n","aioseo_head_json":{"title":"Improved identification of neoantigen-reactive T cells targeting both unique and common oncogenes for personalized cancer immunotherapy | LifeTein Peptide Blog","description":"Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) that target neoantigens can cause tumor regression in certain patients with metastatic epithelial cancer. However, identifying and utilizing neoantigen-reactive T cells for treatment remains challenging, and it is unclear if current detection methods miss clinically significant neoantigen reactivities. To address this, scientists explored whether enriching for T","canonical_url":"https:\/\/www.lifetein.com\/blog\/docs\/improved-identification-of-neoantigen-reactive-t-cells-targeting-both-unique-and-common-oncogenes-for-personalized-cancer-immunotherapy\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"xKDW6DUiGuZ6nwglNeWlVWTgzTtMPzas13ROL63ytTc","msvalidate.01":"5B15601215D876311F84CFEFB0F72F18","miscellaneous":""},"schema":null,"og:locale":"en_US","og:site_name":"LifeTein Peptide Synthesis Blog","og:type":"article","og:title":"Improved identification of neoantigen-reactive T cells targeting both unique and common oncogenes for personalized cancer immunotherapy | LifeTein Peptide Blog","og:description":"Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) that target neoantigens can cause tumor regression in certain patients with metastatic epithelial cancer. However, identifying and utilizing neoantigen-reactive T cells for treatment remains challenging, and it is unclear if current detection methods miss clinically significant neoantigen reactivities. To address this, scientists explored whether enriching for T","og:url":"https:\/\/www.lifetein.com\/blog\/docs\/improved-identification-of-neoantigen-reactive-t-cells-targeting-both-unique-and-common-oncogenes-for-personalized-cancer-immunotherapy\/","fb:admins":"233983946638783","og:image":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg","og:image:secure_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg","article:published_time":"2026-02-28T03:13:48+00:00","article:modified_time":"2026-03-02T15:56:16+00:00","article:publisher":"https:\/\/www.facebook.com\/LifeTein-LLC-233983946638783\/","twitter:card":"summary_large_image","twitter:site":"@lifetein","twitter:title":"Improved identification of neoantigen-reactive T cells targeting both unique and common oncogenes for personalized cancer immunotherapy | LifeTein Peptide Blog","twitter:description":"Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) that target neoantigens can cause tumor regression in certain patients with metastatic epithelial cancer. However, identifying and utilizing neoantigen-reactive T cells for treatment remains challenging, and it is unclear if current detection methods miss clinically significant neoantigen reactivities. To address this, scientists explored whether enriching for T","twitter:creator":"@lifetein","twitter:image":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg"},"aioseo_meta_data":{"post_id":"2767","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","location":null,"local_seo":null,"seo_analyzer_scan_date":null,"breadcrumb_settings":null,"limit_modified_date":false,"open_ai":null,"ai":{"faqs":[],"keyPoints":[],"titles":[],"descriptions":[],"socialPosts":{"email":[],"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2026-02-28 03:13:48","updated":"2026-03-02 15:56:58"},"aioseo_breadcrumb":"

\n\t\t\tHome<\/a>\n\t\t<\/span>»<\/span>\n\t\t\tDocs<\/a>\n\t\t<\/span>»<\/span>\n\t\t\tTechnical Protocols<\/a>\n\t\t<\/span>»<\/span>\n\t\t\tImproved identification of neoantigen-reactive T cells targeting both unique and common oncogenes for personalized cancer immunotherapy\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.lifetein.com\/blog"},{"label":"Docs","link":"https:\/\/www.lifetein.com\/blog\/docs\/"},{"label":"Technical Protocols","link":"https:\/\/www.lifetein.com\/blog\/docs-category\/technical-protocols\/"},{"label":"Improved identification of neoantigen-reactive T cells targeting both unique and common oncogenes for personalized cancer immunotherapy","link":"https:\/\/www.lifetein.com\/blog\/docs\/improved-identification-of-neoantigen-reactive-t-cells-targeting-both-unique-and-common-oncogenes-for-personalized-cancer-immunotherapy\/"}],"year_month":"2026-07","word_count":86,"total_views":0,"reactions":{"happy":0,"normal":0,"sad":0},"author_info":{"name":"lifetein","author_nicename":"new_blog","author_url":"https:\/\/www.lifetein.com\/blog\/author\/new_blog\/"},"doc_category_info":[{"term_name":"Technical Protocols","term_url":"https:\/\/www.lifetein.com\/blog\/docs-category\/technical-protocols\/"}],"doc_tag_info":[],"_links":{"self":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs\/2767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs"}],"about":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/types\/docs"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/comments?post=2767"}],"version-history":[{"count":2,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs\/2767\/revisions"}],"predecessor-version":[{"id":2814,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/docs\/2767\/revisions\/2814"}],"wp:attachment":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/media?parent=2767"}],"wp:term":[{"taxonomy":"doc_category","embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/doc_category?post=2767"},{"taxonomy":"doc_tag","embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/doc_tag?post=2767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}